New Guideline Includes Immunotherapy - Metastatic Breast Cancer Trial Talk

Inside Clinical Trials

In March, the immunotherapy Tecentriq® (atezolizumab) became the first to be included in NCCN Treatment Guidelines for metastatic breast cancer. It can be used along with Abraxane® (nab-paclitaxel) to treat patients with locally advanced or metastatic triple negative breast cancer who have a tumor that tests positive for PD-L1.

Immunotherapy is a type of biological therapy that uses the body’s immune system to fight cancer. There are many new types of immunotherapies being developed and researchers are actively studying which ones might work in patients with breast cancer.

Below you will find relevant information about MBC treatment guidelines as well as research news and clinical trials on immunotherapy for metastatic breast cancer.

Last Modified on February 23, 2021



for past articles or specific information.